摘要
胰腺癌(PC)是最具侵袭性的人类癌症之一,有严重的耐药性和高复发率的特点,中位生存时间为6~12个月。同时胰腺癌也是预后最差的肿瘤之一,其早期临床症状不明显,大部分病人确诊时已无手术机会,需要通过全身化疗来改善预后。因此放化疗对于治疗胰腺癌至关重要。有许多用于胰腺癌治疗的化疗药物可以提高患者的总体生存率。其中研究最为广泛的是吉西他滨耐药。吉西他滨是晚期胰腺癌新辅助治疗、辅助治疗和姑息治疗的基石,胰腺癌的不良预后主要是由于对包括吉西他滨在内的治疗产生耐药性。因此本文就吉西他滨在胰腺癌治疗中的研究进展进行综述。
Pancreatic cancer(PC)is one of the most aggressive human cancers,characterized by severe drug resistance and high recurrence rate,with a median survival time of 6-12 months.At the same time,pancreatic cancer is also one of the tumors with the worst prognosis.Its early clinical symptoms are not obvious,and most patients have no chance of surgery when diagnosed,so systemic chemotherapy is needed to improve the prognosis.So radiotherapy and chemotherapy are very important in the treatment of pancreatic cancer.There are a number of chemotherapy drugs used to treat pancreatic cancer that improve overall survival.Gemcitabine resistance is the most widely studied.Gemcitabine is the cornerstone of neoadjuvant,adjunctive and palliative care for advanced pancreatic cancer,whose poor prognosis is largely due to resistance to treatment including gemcitabine.This article reviews the research progress of gemcitabine in the treatment of pancreatic cancer.
作者
张思楠
张丽娜
Zhang Sinan;Zhang Li’na(Jiamusi University,Jiamusi 154007;Daqing Oilfield General Hospital,Daqing 163411,China)
出处
《广东化工》
CAS
2022年第16期86-87,92,共3页
Guangdong Chemical Industry
关键词
胰腺癌
化疗耐药
吉西他滨
核苷转运蛋白
上皮-间质转化
表皮生长因子受体
pancreatic cancer
chemotherapy resistance
gemcitabine
nucleoside transporter
epithelial-mesenchymal transformation
epidermal growth factor receptor
